Sanofi-Aventis's oral MS drug teriflunomide meets goals in first Phase III trial
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis's teriflunomide reduced the annualized relapse rate and the risk of disability progression compared with placebo in its first Phase III trial, TEMSO, in relapsing multiple sclerosis (RMS).